Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does INFLIXIMAB Cause C-reactive protein abnormal? 2,676 Reports in FDA Database

Grow Your Own Natural Pharmacy at Home

Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.

Get the Kit

According to the FDA Adverse Event Reporting System (FAERS), 2,676 reports of C-reactive protein abnormal have been filed in association with INFLIXIMAB (Renflexis). This represents 1.9% of all adverse event reports for INFLIXIMAB.

2,676
Reports of C-reactive protein abnormal with INFLIXIMAB
1.9%
of all INFLIXIMAB reports
1,062
Deaths
1,744
Hospitalizations

How Dangerous Is C-reactive protein abnormal From INFLIXIMAB?

Of the 2,676 reports, 1,062 (39.7%) resulted in death, 1,744 (65.2%) required hospitalization, and 1,296 (48.4%) were considered life-threatening.

Is C-reactive protein abnormal Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for INFLIXIMAB. However, 2,676 reports have been filed with the FAERS database.

What Other Side Effects Does INFLIXIMAB Cause?

Off label use (34,801) Drug ineffective (33,738) Condition aggravated (16,616) Rheumatoid arthritis (16,251) Pain (15,061) Fatigue (13,473) Arthralgia (13,441) Infusion related reaction (12,946) Product use issue (12,752) Drug intolerance (11,173)

What Other Drugs Cause C-reactive protein abnormal?

METHOTREXATE (3,734) ADALIMUMAB (3,629) ETANERCEPT (3,592) ABATACEPT (3,402) LEFLUNOMIDE (3,279) TOCILIZUMAB (3,259) HYDROXYCHLOROQUINE (3,245) SULFASALAZINE (2,823) RITUXIMAB (2,608) TOFACITINIB (2,062)

Which INFLIXIMAB Alternatives Have Lower C-reactive protein abnormal Risk?

INFLIXIMAB vs INFLIXIMAB-ABDA INFLIXIMAB vs INFLIXIMAB-AXXQ INFLIXIMAB vs INFLIXIMAB-DYYB INFLIXIMAB vs INFLIXIMAB-QBTX INFLIXIMAB vs INFLIXIMAB, RECOMBINANT

Related Pages

INFLIXIMAB Full Profile All C-reactive protein abnormal Reports All Drugs Causing C-reactive protein abnormal INFLIXIMAB Demographics